APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

Current Opinion in Biomedical Engineering is a renowned journal published by Elsevier, focusing on the cutting-edge developments and critical assessments in the fields of biomedical engineering and related disciplines. With an ISSN of 2468-4511, it provides a valuable platform for researchers and professionals to disseminate their insights and discoveries in areas such as bioengineering, biomaterials, and medicine. Its impressive impact factor positions it in the Q2 category for several fields, including Bioengineering and Biomedical Engineering, highlighting its influence and relevance in ongoing scientific dialogues. The journal’s unique format of opinion pieces and reviews encourages innovative thinking and fosters collaboration among experts. As an essential resource for those engaged in the life sciences and engineering, Current Opinion in Biomedical Engineering serves to stimulate discussion, promote knowledge exchange, and drive advancements in biomedical applications. Set in the Netherlands at Radarweg 29, 1043 NX Amsterdam, the journal is accessible through various academic platforms, enabling a global readership to engage with the latest scholarly work in this dynamic field.

Biomaterials Research, published by the American Association for the Advancement of Science, is a prominent open access journal established in 2014, dedicated to advancing the field of biomaterials. Based in the United Kingdom, this journal has swiftly become an essential platform for researchers and practitioners, offering groundbreaking insights in biomaterials, biomedical engineering, ceramics and composites, and miscellaneous medical fields. With its impressive Q1 ranking across multiple relevant categories in 2023 and its strong Scopus rankings, including a remarkable 90th percentile in the medicine category, Biomaterials Research showcases high-quality, peer-reviewed research designed to address both practical and theoretical challenges in biomaterials science. As an open access journal, it promotes wider dissemination and accessibility of research findings, crucial for fostering innovation and collaboration within the scientific community. Researchers, professionals, and students alike are encouraged to contribute, read, and engage with the latest developments in this dynamic field.

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

Bio-Design and Manufacturing, published by SPRINGER HEIDELBERG, is a pioneering journal that stands at the forefront of innovation in the fields of Biomedical Engineering, Biotechnology, Industrial and Manufacturing Engineering, and Materials Science. With its ISSN 2096-5524 and E-ISSN 2522-8552, this journal has established itself as a leading platform for disseminating cutting-edge research and advancements that merge biological principles with manufacturing processes, emphasizing sustainable and efficient practices. It has garnered recognition in the 2023 category quartiles, boasting a Q1 rank in all its relevant fields, which underscores its significance and impact—evident from its prime Scopus rankings that place it within the top percentiles of numerous engineering and materials science disciplines. Researchers, professionals, and students alike benefit from the wealth of knowledge presented in this journal, making it an essential resource for those seeking to enhance their understanding of bio-design applications and innovation in manufacturing processes.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

Stem Cells International is a premier open access journal published by HINDAWI LTD, focusing on the rapidly evolving field of stem cell research. With an ISSN of 1687-966X and E-ISSN 1687-9678, this journal has been a vital resource since its inception in 2010, showcasing innovative studies and breakthroughs up to 2024. Positioned in Q3 in Cell Biology and Q2 in Molecular Biology for 2023, as well as well-ranked in the Scopus database, the journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the implications of stem cell technology in regenerative medicine and biological research. The open access model ensures wide accessibility, fostering collaboration and knowledge-sharing across the scientific community, making it a cornerstone in advancing the understanding and application of stem cell science.